| Market Cap | 105.15M | P/E | - | EPS this Y | 100.00% | Ern Qtrly Grth | - |
| Income | -18.75M | Forward P/E | -2.05 | EPS next Y | - | 50D Avg Chg | - |
| Sales | 33.46M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 28.00% |
| Dividend | N/A | Price/Book | 1.44 | EPS next 5Y | - | 52W High Chg | -29.00% |
| Recommedations | 1.30 | Quick Ratio | 4.26 | Shares Outstanding | 89.53M | 52W Low Chg | 125.00% |
| Insider Own | 5.38% | ROA | -7.54% | Shares Float | 84.69M | Beta | 2.68 |
| Inst Own | 14.85% | ROE | -26.19% | Shares Shorted/Prior | 2.09M/1.83M | Price | 1.15 |
| Gross Margin | 94.01% | Profit Margin | -56.05% | Avg. Volume | 498,775 | Target Price | 5.33 |
| Oper. Margin | 53.75% | Earnings Date | May 13 | Volume | 254,658 | Change | -3.36% |
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
| Truist Securities | Buy | Mar 8, 24 |
| Stifel | Buy | Dec 19, 23 |
| Truist Securities | Buy | Aug 23, 23 |
| EF Hutton | Buy | Aug 7, 23 |
| EF Hutton | Buy | Jun 6, 23 |
| EF Hutton | Buy | May 26, 23 |
| EF Hutton | Buy | May 24, 23 |
| Oppenheimer | Outperform | May 16, 23 |
| Oppenheimer | Outperform | Feb 28, 23 |